HT
ZNTL icon

Headlands Technologies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Headlands Technologies’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70K Buy
+29,899
New +$77.2K 0.01% 682

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Headlands Technologies's ZNTL Position: Q1 2026 in Review

Headlands Technologies opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 29,899 shares worth $70K. The stake represents 0.01% of the portfolio and ranks #682 among its holdings.

102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Headlands Technologies held 29,899 shares of Zentalis Pharmaceuticals worth $70K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Headlands Technologies position in Q1 2026.
  • Zentalis Pharmaceuticals made up 0.01% of Headlands Technologies's portfolio in Q1 2026, its #682 holding.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.